Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 11

Get the latest international news and world events from around the world.

Log in for authorized contributors

New Experimental Drug Shrinks Tumors in Prostate Cancer Clinical Trial

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own immune arsenal to fight cancer.

In the trial, which is still in progress and has not yet undergone peer review, patients with advanced prostate cancer who had failed to respond to other treatments were given VIR-5500.

Remarkably, initial findings showed that in the patients who received the highest doses, 82% saw reductions in their PSA (prostate-specific antigen) levels – a commonly used measure of prostate cancer.

Hair-thin fiber-optic sensors could detect cancer by reading multiple biomarkers

Microscopic sensors that are as thin as a strand of hair but capable of taking multiple measurements simultaneously could revolutionize the diagnosis and monitoring of diseases like cancer. Researchers from Adelaide University’s Institute for Photonics and Advanced Sensing and the University of Stuttgart in Germany worked together to develop the tiny sensors using state-of-the-art, ultrafast 3D micro-printing technology.

The unique sensors target specific biomarkers and are printed directly onto the tip of optical fibers. They’re able to monitor several signals at the same time, including temperature and chemical changes. The paper is published in the journal Advanced Optical Materials.

“This breakthrough could lead to next-generation medical tools that track disease, guide treatment and monitor the body in real time,” said Associate Professor Shahraam Afshar, the project’s lead researcher from Adelaide University’s Institute for Photonics and Advanced Sensing.

Mitochondrial capsule transplantation therapy shows potential for major diseases

Chinese researchers have developed a novel and highly efficient mitochondrial capsule transplantation therapy, achieving the safe and efficient transplantation of healthy mitochondria into cells and tissues for the first time. This new therapy can significantly alleviate symptoms of severe diseases such as Parkinson’s disease.

According to the study, published in the journal Cell, the therapy proposes a brand-new strategy in the field of regenerative medicine, shedding fresh light on intervention in refractory diseases caused by mitochondrial dysfunction, such as mitochondrial genetic diseases and neuron degenerative disorders.

Mitochondria are organelles that refer to specialized subunits with specific functions in cells. Mitochondria function like power plants in cells, continuously converting nutrients into energy for life activities. They are also the only organelles in human cells that possess their own genome.

The function of mRNA quality control in aging and age-related diseases

Aging is a complex biological process characterized by the gradual decline of physiological and molecular functions and increased susceptibility to age-associated diseases. Emerging evidence indicates the role of mRNA quality control mechanisms in the regulation of aging and longevity. This review focuses on the function of mRNA surveillance mechanisms, including nonsense-mediated mRNA decay (NMD), nonstop decay (NSD), and no-go decay (NGD), in aging and age-related diseases. We discuss the critical roles of these pathways in maintaining mRNA quality and preventing the accumulation of aberrant transcripts, which can contribute to aging and age-related disorders.

Tissue and CD4 T cell subset dependence on the amino acid transporter SLC38A1

Metabolic demands and mechanisms of nutrient uptake shape T cell function and offer new therapeutic opportunities, but selective targeting remains challenging. Here, in vivo CRISPR screens show that CD4 T cell metabolism and nutrient uptake vary based on both cell subset and the tissue and inflammatory site.

Scientists discover Alzheimer’s hidden “death switch” in the brain

Scientists have uncovered a hidden “death switch” in the brain that may be driving Alzheimer’s disease—and even found a way to turn it off in mice. The culprit is a toxic pairing of two proteins that, when combined, triggers the destruction of brain cells and fuels memory loss. By using a new compound to break apart this deadly duo, researchers were able to slow disease progression, protect brain cells, and even reduce hallmark amyloid buildup.

Dual immune response may keep HIV in check without medication

Imagine a game of chess where your opponent’s king is in check. It cannot move, but the game is not over—the piece remains on the board. This is how the body might control HIV on its own: The virus would be contained and unable to replicate or spread, but it would not have been eliminated. This is the goal of Professor Ole Schmeltz Søgaard and an international team of researchers—to enable more patients’ immune systems to keep the virus permanently in check without the need for daily medication. Their findings suggest that this requires two key components working in tandem: antibodies and T cells.

In a study published in Nature Immunology, the researchers followed patients who stopped taking their daily HIV medication after receiving experimental treatment. In a small group of patients, the virus has not returned.

“We can see that two branches of the immune system work together to control the virus. One targets one aspect of the virus, the other targets another. Together, they are effective enough to prevent the virus from escaping,” says Søgaard, Professor of Infectious Diseases at Aarhus University Hospital.

Atomic disorder strategy could help high-capacity batteries last longer

Researchers at UNIST, in collaboration with the Pohang Accelerator Laboratory (PAL) and KAIST, have introduced a novel approach to stabilizing high-capacity battery materials. By intentionally inducing atomic-level disorder within lithium-rich layered oxide (LRLO) cathodes, the team has effectively minimized structural degradation and energy losses, paving the way for next-generation batteries with higher energy density and longer lifespan.

The findings of this research have been published online in ACS Energy Letters.

Lithium-rich layered oxides (LRLO) are among the most promising cathode materials for future energy storage solutions due to their exceptional capacity, which involves not only metal ions but also oxygen participating in electrochemical reactions. However, their practical application has been hindered by structural instability during repeated charge and discharge cycles, leading to capacity fade and voltage degradation.

Rubin Alert Leads to First Follow-Up Observations and Detection of Four Supernovae

The Vera C. Rubin Observatory commenced operations last summer with the release of its “first light” images. During its ten-year Legacy Survey of Space and Time (LSST), the observatory will study the Universe for indications of Dark Matter and Dark Energy. It will also create an inventory of objects within the Solar System, and explore the sky for “transient” objects — i.e., those that move or change in brightness. These include asteroids, comets, interstellar objects (ISOs), transient stars, and supernovae.

To ensure follow-up observations of these objects, the National Science Foundation (NSF) has developed a system to enable rapid responses to Rubin-generated alerts. This allows observatories around the world to aim their telescopes at fleeting objects in the night sky and conduct rapid follow-up observations before they disappear. The system was recently validated when Rubin issued a series of alerts that led to the classification of four supernovae, which are a vital tool for measuring the expansion rate of the Universe.

The system incorporates a series of tools developed by NSF’s National Science Foundation National Optical-Infrared Astronomy Research Laboratory (NOIRLab), including an alert-filtering system, an automatic observation request manager, a network of telescopes — the Astronomical Observatory Event Network (AEON) — to conduct observations, and automatic data reduction software. This system helps to process the millions of alerts Rubin is expected to generate every night once the LSST begins.

/* */